Study of people starting immunotherapy for solid tumors
Part of Cancer clinical trials.
This study follows people who are starting their first immune “checkpoint” treatment for a solid cancer. It collects clinic information and lab results to understand how patients respond and what factors matter most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are starting your first immunotherapy that blocks immune checkpoints (like anti–PD-1, anti–PD-L1, or anti–CTLA-4)
- Your cancer is a solid tumor confirmed by a biopsy or tissue test
- Your treatment start is at Centre Oscar Lambret, and it can be for early-stage, recurrence, or metastatic disease
- You can and will sign consent and attend follow-up visits (travel, support, and mental ability to participate)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how your immune system responds to immunotherapy given before surgery for early-stage solid tumors (like lung, head and neck, melanoma, or bladder cancer). The goal is to understand why some people respond better, so doctors can improve treatment for future patients.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study is looking at a specific type of immune cell (called TLR4+ cells) in the blood of people with solid tumors. By studying these cells, researchers hope to learn more about how the immune system reacts to cancer and to treatments.
This study watches people with solid tumors who are starting immunotherapy for the first time. It aims to predict and better understand side effects and how well the treatment works, to help doctors manage care more effectively.
This is an observational study that follows adults with solid cancer who are receiving immune checkpoint inhibitor treatments. It aims to learn how these medicines are used and what outcomes may look like in everyday care.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.